​

Vor Biopharma (VOR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

VOR Stock Forecast

Vor Biopharma (VOR) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $58.00, with a high of $64.00 and a low of $55.00. This represents a 115.37% increase from the last price of $26.93.

- $13 $26 $39 $52 $65 High: $64 Avg: $58 Low: $55 Last Closed Price: $26.93

VOR Stock Rating

Vor Biopharma stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (75.00%), 3 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 0 3 9 Strong Sell Sell Hold Buy Strong Buy

VOR Price Target Upside V Benchmarks

TypeNameUpside
StockVor Biopharma115.37%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts234
Avg Price Target$59.50$58.00$44.25
Last Closing Price$26.93$26.93$26.93
Upside/Downside120.94%115.37%64.31%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25113--5
Sep, 251-4--5
Aug, 251-4--5
Jul, 251-4--5
Jun, 25--5--5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 29, 2025H.C. Wainwright$55.00$26.93104.23%104.23%
Oct 14, 2025Robert W. Baird$64.00$30.81107.72%137.65%
Sep 24, 2025Stephen WilleyStifel Nicolaus$55.00$31.2875.83%104.23%
Jun 30, 2025H.C. Wainwright$3.00$1.6285.19%-88.86%
Apr 27, 2022Goldman Sachs$6.00$5.607.14%-77.72%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 29, 2025H.C. WainwrightBuyBuyhold
Jun 30, 2025H.C. WainwrightBuyBuyupgrade
Sep 06, 2024H.C. WainwrightBuyBuyhold
Aug 14, 2024BarclaysOverweightOverweighthold
Nov 14, 2022OppenheimerOutperformOutperformhold
Jul 27, 2022WedbushOutperforminitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.75$-1.70----
Avg Forecast$-1.88$-1.44$-1.09$-1.07$-0.90$-0.52
High Forecast$-1.82$-1.14$-0.57$-0.50$-0.46$-0.52
Low Forecast$-1.97$-1.67$-1.57$-1.46$-1.43$-0.52
Surprise %-6.91%18.06%----

Revenue Forecast

$0 $19M $38M $57M $76M $95M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$2.00M$25.00M$38.72M$92.69M
High Forecast--$2.00M$25.00M$38.72M$92.69M
Low Forecast--$2.00M$25.00M$38.72M$92.69M
Surprise %------

Net Income Forecast

$-150M $-120M $-90M $-60M $-30M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-117.86M$-116.91M----
Avg Forecast$-127.40M$-94.52M$-72.01M$-65.76M$-63.52M$-34.94M
High Forecast$-122.38M$-76.84M$-38.50M$-33.72M$-31.08M$-34.94M
Low Forecast$-132.41M$-112.21M$-105.51M$-97.79M$-95.95M$-34.94M
Surprise %-7.48%23.69%----

VOR Forecast FAQ

Is Vor Biopharma stock a buy?

Vor Biopharma stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Vor Biopharma is a favorable investment for most analysts.

What is Vor Biopharma's price target?

Vor Biopharma's price target, set by 12 Wall Street analysts, averages $58 over the next 12 months. The price target range spans from $55 at the low end to $64 at the high end, suggesting a potential 115.37% change from the previous closing price of $26.93.

How does Vor Biopharma stock forecast compare to its benchmarks?

Vor Biopharma's stock forecast shows a 115.37% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Vor Biopharma over the past three months?

  • October 2025: 20.00% Strong Buy, 20.00% Buy, 60.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 20.00% Strong Buy, 0% Buy, 80.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 20.00% Strong Buy, 0% Buy, 80.00% Hold, 0% Sell, 0% Strong Sell.

What is Vor Biopharma’s EPS forecast?

Vor Biopharma's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.09, marking a -35.88% decrease from the reported $-1.7 in 2024. Estimates for the following years are $-1.07 in 2026, $-0.9 in 2027, and $-0.52 in 2028.

What is Vor Biopharma’s revenue forecast?

Vor Biopharma's average annual revenue forecast for its fiscal year ending in December 2025 is $2M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $25M, followed by $38.72M for 2027, and $92.7M for 2028.

What is Vor Biopharma’s net income forecast?

Vor Biopharma's net income forecast for the fiscal year ending in December 2025 stands at $-72.006M, representing a -38.41% decrease from the reported $-117M in 2024. Projections indicate $-65.758M in 2026, $-63.515M in 2027, and $-34.94M in 2028.